Cancer Family
Malignant Breast Neoplasm
CI-CAN-00000227Explore in graph →
Top-level2,628 active trials43 approved drugs310 evidence items
- NCIt
- C9335
- ICD-10
- C50
- DOID
- 1612
- Other
- 2 more codes
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000227Explore in graph →
Clinical trials
12,359 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,368)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04345913 | Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04491942 | Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer | active not recruiting | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 2 |
| Jul 31, 2026 |
| clinicaltrials |
| NCT05715255 | Adaptive Symptom Self-Management Immunotherapy Study | active not recruiting | N/A | 400 | University of ArizonaOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT03168737 | 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients | active not recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT05896189 | Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | active not recruiting | N/A | 386 | NRG OncologyOTHER | 2 | Jul 30, 2026 | clinicaltrials |
| NCT06419621 | PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC | active not recruiting | Phase 3 | 392 | Biotheus Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT06445400 | A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 2 | 83 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT02445391 | Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy | active not recruiting | Phase 3 | 415 | ECOG-ACRIN Cancer Research GroupNETWORK | 2 | Jul 27, 2026 | clinicaltrials |
| NCT04243616 | Cemiplimab in High-risk or Locally Advanced Luminal and Triple Negative Breast Cancer(CemiHALT) | active not recruiting | Phase 2 | 36 | Medical College of WisconsinOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT02942355 | Trial of Anastrozole and Palbociclib in Metastatic HER2-Negative Breast Cancer | active not recruiting | Phase 2 | 40 | Wake Forest University Health SciencesOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03915678 | Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors(AGADIR) | active not recruiting | Phase 2 | 247 | Institut BergoniéOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT04461808 | Tomosynthesis as Primary Test for Breast Cancer Screening(MAITA) | active not recruiting | N/A | 10,156 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | Jul 24, 2026 | clinicaltrials |
| NCT06295744 | Outcomes and Cosmesis With Whole Breast Irradiation and Boost | active not recruiting | N/A | 50 | University of Wisconsin, MadisonOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT03975647 | A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | active not recruiting | Phase 3 | 466 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 20 | Jul 23, 2026 | clinicaltrials |
| NCT04595435 | IORT-Breast at Medical Center Navicent Health(IORT-Breast) | active not recruiting | — | 94 | Wake Forest University Health SciencesOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT05455658 | STEMVAC in Patients With Early Stage Triple Negative Breast Cancer | active not recruiting | Phase 2 | 33 | University of WashingtonOTHER | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06316531 | A Study Comparing BL-M07D1 With T-DM1 in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer | active not recruiting | Phase 3 | 274 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT06382142 | A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02) | active not recruiting | Phase 3 | 418 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 23, 2026 | clinicaltrials |
| NCT02414269 | Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin | active not recruiting | Phase 1 / Phase 2 | 113 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03546686 | Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | active not recruiting | Phase 2 | 51 | University of Texas Southwestern Medical CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT03990610 | An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients With Breast Cancer Undergoing Breast Reconstruction | active not recruiting | N/A | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 22, 2026 | clinicaltrials |
| NCT06157892 | A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | active not recruiting | Phase 2 | 54 | Seagen, a wholly owned subsidiary of PfizerINDUSTRY | 10 | Jul 22, 2026 | clinicaltrials |
| NCT03255577 | Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer | active not recruiting | N/A | 162 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03495011 | MRI Characterization of Mammographically Detected DCIS | active not recruiting | — | 122 | University of WashingtonOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT04549207 | Comparing Continuation or De-escalation of Bone Modifying Agents (BMA) in Patients Treated for Over 2 Years for Bone Metastases From Either Breast or Castration-resistant Prostate Cancer | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05552001 | Safety and Efficacy Analysis of an Antibody Associated With a Chemotherapy for Patients With a Triple Negative Metastatic Breast Cancer(ISIdE) | active not recruiting | Phase 3 | 96 | UNICANCEROTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT05612100 | Endocrine Therapy-Induced Alopecia in Postmenopausal and Premenopausal Female Breast Cancer Patients | active not recruiting | — | 169 | Mayo ClinicOTHER | 1 | Jul 21, 2026 | clinicaltrials |
| NCT03414658 | The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast Cancer | active not recruiting | Phase 2 | 100 | Adrienne G. WaksOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT05078047 | Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO(MOIO) | active not recruiting | Phase 3 | 646 | UNICANCEROTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT06758102 | Dance Study for Post-surgical Pain in Breast Cancer Survivors | active not recruiting | N/A | 28 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 17, 2026 | clinicaltrials |
| NCT07710716 | A Real-World Study of Clinical Adoption, Treatment Patterns and Tolerability of Adjuvant Ribociclib in HR+/HER2- Early Breast Cancer Patients(CATTALYST) | active not recruiting | — | 3,000 | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 17, 2026 | clinicaltrials |
| NCT02792114 | T-Cell Therapy for Advanced Breast Cancer | active not recruiting | Phase 1 | 186 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT04115306 | Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer(Dauntless-1) | active not recruiting | Phase 1 / Phase 2 | 61 | Phoenix Molecular DesignsINDUSTRY | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05633979 | Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer | active not recruiting | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT05754528 | Evaluating an Endocrine Therapy Dose-frequency Escalation Strategy and Its Effects on Tolerability and Compliance(REaCT-TEMPO) | active not recruiting | Phase 4 | 240 | Ottawa Hospital Research InstituteOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT02276443 | Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative | active not recruiting | N/A | 798 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02411656 | Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy | active not recruiting | Phase 2 | 71 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT02912312 | Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer | active not recruiting | Phase 2 | 805 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT06533059 | A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | active not recruiting | Phase 1 | 110 | Alterome Therapeutics, Inc.INDUSTRY | 8 | Jul 15, 2026 | clinicaltrials |
| NCT07692464 | Training On Self-Breast Examination Using Visual Breast Examination Materials For İlliterate Women. | active not recruiting | N/A | 156 | Inonu UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT07704801 | CDK4/6 Inhibitors in Metastatic HR-Positive Breast Cancer(OCDMBC) | active not recruiting | — | 300 | Sohag UniversityOTHER | 1 | Jul 15, 2026 | clinicaltrials |
| NCT01116648 | Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 155 | National Cancer Institute (NCI)NIH | 1 | Jul 14, 2026 | clinicaltrials |
| NCT01505400 | Integrated Molecular Profiling in Advanced Cancers Trial(IMPACT) | active not recruiting | — | 3,026 | University Health Network, TorontoOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT02032823 | Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer(OlympiA) | active not recruiting | Phase 3 | 1,837 | AstraZenecaINDUSTRY | 24 | Jul 14, 2026 | clinicaltrials |
| NCT02240472 | Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial. | active not recruiting | N/A | 2,766 | Karolinska InstitutetOTHER | 3 | Jul 14, 2026 | clinicaltrials |
| NCT04039230 | Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. | active not recruiting | Phase 1 / Phase 2 | 75 | Massachusetts General HospitalOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT05223322 | Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction(DECODE) | active not recruiting | N/A | 80 | Medical College of WisconsinOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT06557148 | A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer | active not recruiting | — | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07342309 | Real-World Treatment Patterns and Outcomes in HER2-Altered Metastatic Breast Cancer Patients in the United States | active not recruiting | — | 7,933 | Boehringer IngelheimINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
| NCT07386938 | A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer | active not recruiting | Phase 3 | 246 | R-PharmINDUSTRY | 1 | Jul 14, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 31, 2026source: clinicaltrials